Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Anne Fuhlbrigge

Concepts (429)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Asthma
96
2024
2225
8.900
 Why?
Adrenal Cortex Hormones
27
2024
524
3.260
 Why?
Anti-Asthmatic Agents
27
2024
374
3.080
 Why?
Forced Expiratory Volume
19
2019
506
1.610
 Why?
Pulmonary Disease, Chronic Obstructive
11
2022
984
1.430
 Why?
Severity of Illness Index
20
2020
2739
1.020
 Why?
Administration, Inhalation
24
2024
667
0.930
 Why?
Anti-Inflammatory Agents
10
2016
482
0.910
 Why?
Lung Transplantation
10
2017
289
0.890
 Why?
Albuterol
5
2015
105
0.870
 Why?
Bronchodilator Agents
12
2016
241
0.840
 Why?
Budesonide
14
2016
89
0.820
 Why?
Nedocromil
11
2016
32
0.740
 Why?
Self Report
3
2023
799
0.730
 Why?
Humans
126
2025
129626
0.720
 Why?
Nasal Polyps
1
2021
59
0.720
 Why?
Endpoint Determination
2
2020
76
0.700
 Why?
Pharmacogenetics
2
2015
172
0.690
 Why?
Food Hypersensitivity
1
2022
176
0.640
 Why?
Sinusitis
1
2021
211
0.620
 Why?
Lung
7
2019
3938
0.610
 Why?
Virus Diseases
1
2021
210
0.610
 Why?
Physicians
2
2021
866
0.600
 Why?
Hospitalization
13
2020
2057
0.600
 Why?
Glucocorticoids
4
2022
580
0.590
 Why?
Remote Consultation
3
2025
46
0.590
 Why?
Symptom Assessment
1
2019
125
0.580
 Why?
Sleep Apnea, Obstructive
1
2021
275
0.550
 Why?
Oxygen Inhalation Therapy
4
2020
143
0.540
 Why?
Child
53
2022
20884
0.530
 Why?
Androstadienes
3
2012
106
0.530
 Why?
Bone Density
2
2014
463
0.520
 Why?
Emergency Service, Hospital
9
2013
1914
0.520
 Why?
Disease Progression
14
2020
2627
0.520
 Why?
Male
81
2024
63670
0.510
 Why?
Managed Care Programs
8
2008
133
0.510
 Why?
Precision Medicine
1
2020
387
0.500
 Why?
Adult
46
2024
35599
0.500
 Why?
Female
80
2024
68734
0.480
 Why?
Patient Reported Outcome Measures
1
2018
374
0.470
 Why?
Cost Savings
1
2015
78
0.460
 Why?
Practice Patterns, Physicians'
7
2020
1271
0.460
 Why?
Adrenergic beta-2 Receptor Agonists
4
2020
36
0.460
 Why?
Middle Aged
39
2024
31136
0.420
 Why?
Cost-Benefit Analysis
7
2022
569
0.420
 Why?
Peak Expiratory Flow Rate
2
2011
36
0.420
 Why?
Comorbidity
4
2021
1547
0.380
 Why?
Surveys and Questionnaires
14
2022
5415
0.360
 Why?
Adolescent
37
2019
20412
0.360
 Why?
Quality of Life
12
2023
2688
0.350
 Why?
Administration, Oral
6
2021
787
0.350
 Why?
Mentors
1
2012
177
0.350
 Why?
Medical Records Systems, Computerized
3
2008
93
0.350
 Why?
United States
23
2022
13871
0.340
 Why?
Respiratory Function Tests
10
2015
581
0.330
 Why?
Child, Preschool
31
2016
10490
0.330
 Why?
Medication Adherence
3
2023
558
0.330
 Why?
Faculty, Medical
1
2012
262
0.320
 Why?
Interprofessional Relations
3
2021
277
0.320
 Why?
Child Development
1
2014
460
0.320
 Why?
Spirometry
8
2020
255
0.320
 Why?
Treatment Outcome
15
2017
10219
0.310
 Why?
Aged
22
2022
22061
0.300
 Why?
Oxygen
3
2018
915
0.300
 Why?
Group Practice
1
2008
7
0.300
 Why?
Anti-Allergic Agents
2
2008
45
0.290
 Why?
Computer Simulation
1
2012
939
0.290
 Why?
Phenotype
5
2021
3075
0.280
 Why?
Dyspnea
3
2022
239
0.270
 Why?
Drug Utilization
4
2005
171
0.260
 Why?
Primary Health Care
5
2025
1686
0.260
 Why?
Follow-Up Studies
17
2017
4894
0.260
 Why?
Primary Graft Dysfunction
2
2017
29
0.250
 Why?
Quality Assurance, Health Care
1
2008
317
0.250
 Why?
Bronchiolitis Obliterans
3
2017
68
0.240
 Why?
Randomized Controlled Trials as Topic
7
2020
1365
0.240
 Why?
Gift Giving
1
2005
11
0.240
 Why?
Diagnostic Techniques, Respiratory System
1
2005
5
0.240
 Why?
Allergists
2
2022
12
0.240
 Why?
Respiratory Sounds
1
2006
118
0.240
 Why?
Genetic Testing
1
2008
430
0.240
 Why?
Delivery of Health Care
2
2021
898
0.230
 Why?
Cohort Studies
14
2013
5426
0.230
 Why?
Time Factors
10
2020
6555
0.220
 Why?
Antibodies, Monoclonal
2
2008
1366
0.220
 Why?
Leadership
2
2022
357
0.220
 Why?
Specialization
2
2025
145
0.220
 Why?
Natural Language Processing
1
2025
94
0.220
 Why?
Retrospective Studies
17
2022
14522
0.220
 Why?
Massachusetts
5
2016
159
0.220
 Why?
Medicine
1
2025
119
0.210
 Why?
Genetic Variation
1
2008
939
0.210
 Why?
Recurrence
5
2013
1011
0.200
 Why?
Rhinitis, Allergic, Perennial
1
2003
23
0.200
 Why?
Health Status
1
2008
756
0.200
 Why?
Steroids
8
2011
158
0.200
 Why?
Predictive Value of Tests
9
2012
1947
0.200
 Why?
Young Adult
11
2019
12455
0.200
 Why?
Multicenter Studies as Topic
4
2018
286
0.200
 Why?
Prevalence
4
2022
2564
0.190
 Why?
Beclomethasone
1
2022
27
0.190
 Why?
Models, Theoretical
4
2007
546
0.190
 Why?
Academic Medical Centers
2
2022
475
0.180
 Why?
Desensitization, Immunologic
1
2022
90
0.180
 Why?
Tiotropium Bromide
2
2018
19
0.180
 Why?
Biomarkers
3
2021
3968
0.180
 Why?
Nebulizers and Vaporizers
2
2020
83
0.180
 Why?
Patient Preference
1
2023
184
0.180
 Why?
Social Class
2
2022
259
0.180
 Why?
Electronic Health Records
2
2025
973
0.170
 Why?
Churg-Strauss Syndrome
1
2020
25
0.170
 Why?
Bronchoconstriction
3
2011
31
0.170
 Why?
Pulmonologists
1
2020
15
0.170
 Why?
Granulomatosis with Polyangiitis
1
2020
43
0.170
 Why?
Capacity Building
1
2021
59
0.170
 Why?
Muscarinic Antagonists
1
2020
27
0.170
 Why?
Agammaglobulinemia
1
2020
33
0.170
 Why?
Physician-Patient Relations
2
2021
540
0.170
 Why?
Risk Factors
12
2018
9786
0.170
 Why?
Practice Guidelines as Topic
5
2020
1501
0.160
 Why?
Air Pollution, Indoor
2
2002
141
0.160
 Why?
Treatment Adherence and Compliance
1
2019
24
0.150
 Why?
Exercise Test
1
2022
613
0.150
 Why?
Receptors, IgE
2
2009
44
0.150
 Why?
Prognosis
8
2017
3774
0.150
 Why?
Allergens
1
2021
385
0.140
 Why?
Vitamin D
2
2012
381
0.140
 Why?
Emergency Medical Services
2
2007
522
0.140
 Why?
Fossil Fuels
1
1997
8
0.140
 Why?
Hypersensitivity
1
2020
249
0.140
 Why?
Alemtuzumab
1
2017
15
0.140
 Why?
Drug Prescriptions
2
2011
248
0.140
 Why?
Photopheresis
1
2017
9
0.140
 Why?
Biological Products
1
2020
205
0.140
 Why?
Respiration
1
2017
192
0.130
 Why?
Aged, 80 and over
6
2019
7052
0.130
 Why?
Respiration Disorders
1
1997
72
0.130
 Why?
Physicians, Primary Care
3
2021
228
0.130
 Why?
Drug Combinations
3
2012
331
0.130
 Why?
Socioeconomic Factors
4
2022
1213
0.130
 Why?
Statistics, Nonparametric
1
2017
419
0.130
 Why?
Immunomodulation
1
2017
92
0.130
 Why?
Drug Therapy, Combination
5
2020
1042
0.130
 Why?
Patient Admission
1
2018
183
0.130
 Why?
Breath Tests
2
2008
87
0.130
 Why?
Scopolamine Derivatives
1
2015
7
0.120
 Why?
Immunoglobulin G
1
2020
851
0.120
 Why?
Embolism, Fat
1
2015
11
0.120
 Why?
Tobacco Smoke Pollution
2
2010
231
0.120
 Why?
Transplants
1
2015
35
0.120
 Why?
Cholinergic Antagonists
1
2015
29
0.120
 Why?
National Heart, Lung, and Blood Institute (U.S.)
1
2015
103
0.120
 Why?
Fluticasone-Salmeterol Drug Combination
2
2012
12
0.120
 Why?
Referral and Consultation
1
2021
730
0.120
 Why?
Genomics
2
2018
718
0.120
 Why?
Postoperative Complications
2
2017
2477
0.120
 Why?
Carcinoma, Bronchogenic
1
2015
19
0.120
 Why?
Longitudinal Studies
6
2017
2720
0.120
 Why?
Overweight
2
2011
531
0.120
 Why?
Telemedicine
1
2023
792
0.110
 Why?
Respiratory Tract Infections
2
2012
376
0.110
 Why?
Ambulatory Care Information Systems
2
2005
5
0.110
 Why?
Graft Rejection
2
2013
598
0.110
 Why?
Guideline Adherence
3
2020
527
0.110
 Why?
Prednisolone
1
2014
82
0.110
 Why?
Environmental Exposure
3
2006
463
0.110
 Why?
Risk
4
2015
855
0.110
 Why?
Education, Medical, Continuing
2
2005
122
0.110
 Why?
Quality Improvement
1
2022
1101
0.110
 Why?
Airway Obstruction
1
2015
152
0.110
 Why?
Forecasting
1
2015
361
0.100
 Why?
Transplantation
1
2013
31
0.100
 Why?
Bronchial Hyperreactivity
3
2010
109
0.100
 Why?
Office Visits
4
2011
86
0.100
 Why?
Medicare
2
2022
708
0.100
 Why?
Insurance Claim Review
1
2013
64
0.100
 Why?
Peer Group
2
2012
227
0.100
 Why?
Double-Blind Method
5
2010
1875
0.100
 Why?
Antibodies, Monoclonal, Humanized
2
2008
757
0.100
 Why?
Research
1
2015
419
0.100
 Why?
Growth
1
2012
59
0.100
 Why?
Cost of Illness
3
2003
277
0.100
 Why?
Costs and Cost Analysis
1
2013
201
0.100
 Why?
Methacholine Chloride
3
2008
52
0.100
 Why?
Cytomegalovirus Infections
2
2012
189
0.100
 Why?
Metered Dose Inhalers
1
2012
14
0.100
 Why?
Feedback
1
2012
162
0.100
 Why?
Drug Dosage Calculations
1
2011
22
0.090
 Why?
Mycoses
1
2012
72
0.090
 Why?
Logistic Models
5
2017
1986
0.090
 Why?
Antifungal Agents
1
2012
130
0.090
 Why?
Body Height
1
2012
192
0.090
 Why?
Effect Modifier, Epidemiologic
1
2011
12
0.090
 Why?
Professional Role
1
2012
157
0.090
 Why?
Multivariate Analysis
7
2017
1499
0.090
 Why?
Morbidity
2
2022
302
0.090
 Why?
Medication Errors
1
2012
96
0.090
 Why?
Obesity
3
2015
2882
0.090
 Why?
Epidemiologic Studies
1
2011
64
0.090
 Why?
Patient Readmission
1
2016
653
0.090
 Why?
Mycobacterium
1
2012
106
0.090
 Why?
Diagnostic Errors
1
2012
162
0.090
 Why?
Secondary Prevention
1
2012
219
0.090
 Why?
Pneumococcal Vaccines
1
2012
141
0.090
 Why?
Lung Diseases
1
2017
741
0.090
 Why?
Program Development
1
2012
355
0.090
 Why?
Drug Resistance
1
2011
165
0.090
 Why?
Vitamin D Deficiency
1
2012
177
0.080
 Why?
Probability
1
2011
306
0.080
 Why?
Ambulatory Care
2
2011
506
0.080
 Why?
Chi-Square Distribution
2
2017
515
0.080
 Why?
Decision Support Techniques
2
2012
398
0.080
 Why?
Bronchial Provocation Tests
2
2008
51
0.080
 Why?
Incidence
5
2020
2641
0.080
 Why?
Fluticasone
2
2008
90
0.080
 Why?
Algorithms
1
2017
1616
0.080
 Why?
Immunoglobulin E
2
2008
330
0.080
 Why?
Vital Capacity
4
2017
289
0.080
 Why?
Receptors, Corticotropin-Releasing Hormone
1
2009
27
0.080
 Why?
Lectins, C-Type
1
2009
71
0.080
 Why?
Proportional Hazards Models
1
2012
1198
0.080
 Why?
Cross-Sectional Studies
6
2010
5075
0.080
 Why?
Health Knowledge, Attitudes, Practice
2
2012
1280
0.080
 Why?
Health Services
2
2007
99
0.080
 Why?
Surgical Wound Infection
1
2012
283
0.080
 Why?
Pandemics
3
2022
1491
0.080
 Why?
Odds Ratio
4
2017
1019
0.080
 Why?
Smoking
3
2017
1500
0.080
 Why?
Medication Therapy Management
1
2010
72
0.080
 Why?
Kaplan-Meier Estimate
3
2016
851
0.080
 Why?
Acute Disease
1
2011
979
0.080
 Why?
Vitamin K Epoxide Reductases
1
2008
12
0.080
 Why?
Cytochrome P-450 CYP2C9
1
2008
20
0.080
 Why?
Eosinophil Cationic Protein
1
2008
10
0.070
 Why?
Mixed Function Oxygenases
1
2008
41
0.070
 Why?
Program Evaluation
1
2012
875
0.070
 Why?
Aryl Hydrocarbon Hydroxylases
1
2008
48
0.070
 Why?
Genetic Predisposition to Disease
1
2016
2274
0.070
 Why?
Genetic Techniques
1
2008
63
0.070
 Why?
Quality-Adjusted Life Years
2
2006
106
0.070
 Why?
Markov Chains
2
2006
117
0.070
 Why?
Trastuzumab
1
2008
100
0.070
 Why?
Insurance, Pharmaceutical Services
1
2008
23
0.070
 Why?
Cost Sharing
1
2008
14
0.070
 Why?
Interviews as Topic
1
2011
704
0.070
 Why?
State Health Plans
1
2008
32
0.070
 Why?
Adrenergic beta-Agonists
1
2008
133
0.070
 Why?
Smoking Cessation
1
2012
408
0.070
 Why?
Reimbursement Mechanisms
1
2008
84
0.070
 Why?
Chronic Disease
3
2017
1720
0.070
 Why?
Antibodies, Anti-Idiotypic
1
2007
58
0.070
 Why?
Health Services Accessibility
2
2021
903
0.070
 Why?
Warfarin
1
2008
147
0.070
 Why?
Exercise Tolerance
2
2022
273
0.070
 Why?
Mycobacterium Infections, Nontuberculous
1
2012
353
0.070
 Why?
Omalizumab
1
2007
50
0.070
 Why?
Tomography, X-Ray Computed
1
2017
2512
0.070
 Why?
Factor Analysis, Statistical
1
2008
284
0.070
 Why?
Databases, Factual
1
2012
1269
0.070
 Why?
Health Surveys
2
2006
493
0.070
 Why?
Antiviral Agents
1
2012
715
0.070
 Why?
Influenza Vaccines
1
2012
532
0.070
 Why?
Lung Diseases, Interstitial
1
2013
610
0.070
 Why?
Animals, Domestic
1
2006
15
0.070
 Why?
Receptor, ErbB-2
1
2008
326
0.060
 Why?
Biomedical Research
1
2012
640
0.060
 Why?
Eosinophils
1
2008
324
0.060
 Why?
Physicians, Family
2
2004
206
0.060
 Why?
Models, Biological
1
2012
1724
0.060
 Why?
Health Benefit Plans, Employee
1
2005
22
0.060
 Why?
Database Management Systems
1
2005
48
0.060
 Why?
Health Policy
1
2008
353
0.060
 Why?
Patients
1
2006
169
0.060
 Why?
Hip Fractures
1
2006
82
0.060
 Why?
Infant
3
2008
8995
0.060
 Why?
Insurance Coverage
1
2006
219
0.060
 Why?
Clinical Competence
1
2012
1017
0.060
 Why?
Patient Education as Topic
3
2005
737
0.060
 Why?
Body Mass Index
3
2015
2274
0.060
 Why?
Utilization Review
1
2004
36
0.060
 Why?
Mass Screening
1
2012
1190
0.050
 Why?
Gene Expression Profiling
1
2011
1687
0.050
 Why?
Prenatal Exposure Delayed Effects
1
2010
574
0.050
 Why?
Medicaid
1
2008
431
0.050
 Why?
Anticoagulants
1
2008
637
0.050
 Why?
Vaccination
1
2012
1347
0.050
 Why?
Sex Factors
3
2016
1970
0.050
 Why?
Anti-Bacterial Agents
2
2004
1705
0.050
 Why?
Attitude to Health
1
2006
433
0.050
 Why?
Nitric Oxide
1
2008
895
0.050
 Why?
Circadian Rhythm
1
2006
413
0.050
 Why?
Clinical Trials as Topic
2
2005
1005
0.050
 Why?
Parents
3
2006
1316
0.050
 Why?
Case Management
1
2003
63
0.050
 Why?
Puerto Rico
1
2022
52
0.050
 Why?
Choice Behavior
1
2004
168
0.050
 Why?
Symptom Flare Up
1
2022
38
0.050
 Why?
Lung Neoplasms
1
2015
2342
0.050
 Why?
Sputum
1
2004
302
0.050
 Why?
Academies and Institutes
1
2022
50
0.050
 Why?
Minority Groups
1
2003
249
0.050
 Why?
Health Services Research
1
2004
391
0.050
 Why?
Survival Rate
2
2016
1872
0.040
 Why?
Clinical Trials, Phase II as Topic
1
2020
72
0.040
 Why?
Electronics
1
2021
74
0.040
 Why?
Clinical Trials, Phase III as Topic
1
2020
93
0.040
 Why?
Sample Size
1
2020
116
0.040
 Why?
Efficiency
1
2021
91
0.040
 Why?
Health Care Reform
1
2021
101
0.040
 Why?
Schools, Medical
1
2021
136
0.040
 Why?
Patient Selection
2
2020
661
0.040
 Why?
Risk Assessment
3
2020
3262
0.040
 Why?
Pragmatic Clinical Trials as Topic
1
2020
62
0.040
 Why?
Patient Compliance
2
2016
565
0.040
 Why?
Language
1
2022
283
0.040
 Why?
Stress, Psychological
1
2007
1068
0.040
 Why?
Time
1
2019
76
0.040
 Why?
Cluster Analysis
2
2014
482
0.040
 Why?
Health Education
1
2002
335
0.040
 Why?
Quality of Health Care
1
2003
604
0.040
 Why?
Republic of Korea
1
2017
29
0.040
 Why?
Poland
1
2017
31
0.040
 Why?
Bronchitis, Chronic
1
2017
19
0.040
 Why?
Cooperative Behavior
1
2021
433
0.040
 Why?
Sensitivity and Specificity
3
2013
1843
0.040
 Why?
Patient-Centered Care
1
2003
508
0.030
 Why?
Nitrogen Dioxide
1
1997
32
0.030
 Why?
Long-Term Care
1
2018
92
0.030
 Why?
Geography
1
2018
187
0.030
 Why?
Antineoplastic Agents
1
2008
2046
0.030
 Why?
Self Concept
1
2019
237
0.030
 Why?
Pediatrics
1
2005
1056
0.030
 Why?
Aftercare
1
2019
203
0.030
 Why?
Monitoring, Physiologic
2
2012
265
0.030
 Why?
Netherlands
1
2016
77
0.030
 Why?
Tuberculosis, Pulmonary
1
2017
135
0.030
 Why?
Perception
1
2019
344
0.030
 Why?
Feasibility Studies
1
2020
869
0.030
 Why?
Formoterol Fumarate
1
2015
7
0.030
 Why?
Forced Expiratory Flow Rates
1
2015
13
0.030
 Why?
Ethanolamines
1
2015
17
0.030
 Why?
Salmeterol Xinafoate
1
2015
41
0.030
 Why?
Receptors, Adrenergic, beta-2
1
2015
46
0.030
 Why?
Treatment Failure
1
2016
339
0.030
 Why?
Self Efficacy
1
2019
377
0.030
 Why?
Dose-Response Relationship, Drug
2
2011
2011
0.030
 Why?
Polymorphism, Single Nucleotide
2
2016
2060
0.030
 Why?
Postoperative Period
1
2016
330
0.030
 Why?
Education
1
2015
101
0.030
 Why?
Age Factors
3
2008
3152
0.030
 Why?
Fatal Outcome
1
2015
300
0.030
 Why?
Immunosuppressive Agents
2
2015
858
0.030
 Why?
Pilot Projects
1
2020
1592
0.030
 Why?
Patient Acceptance of Health Care
1
2021
761
0.030
 Why?
Biopsy
2
2013
1088
0.030
 Why?
Combined Modality Therapy
1
2017
1203
0.030
 Why?
Gene Expression
1
2018
1465
0.030
 Why?
Telephone
2
2005
167
0.030
 Why?
Echinocandins
1
2012
7
0.030
 Why?
Lipopeptides
1
2012
13
0.030
 Why?
Tissue Donors
1
2015
391
0.030
 Why?
Amphotericin B
1
2012
29
0.020
 Why?
Aspergillosis
1
2012
20
0.020
 Why?
Intention to Treat Analysis
1
2012
68
0.020
 Why?
Candidiasis
1
2012
57
0.020
 Why?
Extracorporeal Membrane Oxygenation
1
2015
286
0.020
 Why?
Transplantation, Homologous
1
2013
402
0.020
 Why?
Hypoxia
1
2019
1084
0.020
 Why?
Mycobacterium avium Complex
1
2012
88
0.020
 Why?
Age Distribution
2
2003
373
0.020
 Why?
Cromolyn Sodium
2
2001
11
0.020
 Why?
Triazoles
1
2012
148
0.020
 Why?
Leukotriene Antagonists
1
2011
43
0.020
 Why?
Self Care
2
2005
363
0.020
 Why?
Functional Residual Capacity
1
2010
8
0.020
 Why?
Colorado
1
2021
4404
0.020
 Why?
Reference Values
1
2012
794
0.020
 Why?
Costa Rica
1
2010
16
0.020
 Why?
Principal Component Analysis
1
2011
190
0.020
 Why?
Nontuberculous Mycobacteria
1
2012
204
0.020
 Why?
Health
1
2010
75
0.020
 Why?
Genome-Wide Association Study
1
2016
1326
0.020
 Why?
Inhalation
1
2010
28
0.020
 Why?
Environment
1
2011
348
0.020
 Why?
Observation
1
2008
51
0.020
 Why?
Sex Ratio
1
2008
13
0.020
 Why?
Prospective Studies
2
2012
7135
0.020
 Why?
Least-Squares Analysis
1
2008
79
0.020
 Why?
Models, Econometric
1
2008
33
0.020
 Why?
Health Services Administration
1
2007
8
0.020
 Why?
Social Isolation
1
2007
59
0.020
 Why?
Treatment Refusal
1
2008
90
0.020
 Why?
Puberty
1
2008
143
0.020
 Why?
Intelligence
1
2007
132
0.020
 Why?
Body Weight
1
2011
940
0.020
 Why?
Child Behavior Disorders
1
2007
135
0.020
 Why?
Exercise
1
2016
1928
0.010
 Why?
Insurance, Health
1
2007
267
0.010
 Why?
CD4-Positive T-Lymphocytes
1
2011
1058
0.010
 Why?
Animals
1
2006
35391
0.010
 Why?
Genotype
1
2009
1833
0.010
 Why?
Bronchoconstrictor Agents
1
2003
16
0.010
 Why?
Health Status Indicators
1
2004
166
0.010
 Why?
Organizational Innovation
1
2004
139
0.010
 Why?
Case-Control Studies
1
2010
3378
0.010
 Why?
Systems Integration
1
2003
37
0.010
 Why?
Computer Systems
1
2003
44
0.010
 Why?
Motor Activity
1
2007
676
0.010
 Why?
Child Welfare
1
2004
210
0.010
 Why?
Histamine H1 Antagonists
1
2002
29
0.010
 Why?
Self Disclosure
1
2002
62
0.010
 Why?
Drug Administration Schedule
1
2004
767
0.010
 Why?
Administration, Intranasal
1
2002
84
0.010
 Why?
Confidence Intervals
1
2002
317
0.010
 Why?
Nurse's Role
1
2003
140
0.010
 Why?
Regression Analysis
1
2003
997
0.010
 Why?
Point-of-Care Systems
1
2003
148
0.010
 Why?
Health Care Surveys
1
2002
557
0.010
 Why?
Sex Distribution
1
2001
360
0.010
 Why?
Caregivers
1
2007
806
0.010
 Why?
Decision Support Systems, Clinical
1
2003
205
0.010
 Why?
Patient Satisfaction
1
2004
633
0.010
 Why?
Disease Management
1
2003
588
0.010
 Why?
Linear Models
1
2002
819
0.010
 Why?
Bronchoscopy
1
2000
216
0.010
 Why?
Internet
1
2003
618
0.010
 Why?
Pregnancy
1
2010
6417
0.010
 Why?
Survival Analysis
1
2000
1269
0.010
 Why?
Infant, Newborn
1
2004
5756
0.010
 Why?
Fuhlbrigge's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (429) concept(s)
_
Co-Authors Expand Description
See all (19) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)